Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
Patrizia MondelloMichael MianPublished in: Hematological oncology (2019)
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years, remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Despite these findings, the current standard of care for DLBCL patients is still R-CHOP, and optimization of frontline therapy remains an important goal. In this review, we summarize recent updates on the evolution of frontline therapies for DLBCL.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- end stage renal disease
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- small molecule
- single cell
- palliative care
- prognostic factors
- cell therapy
- peritoneal dialysis
- single molecule
- copy number
- gene expression
- stem cells
- chronic pain
- bone marrow
- dna methylation
- mesenchymal stem cells
- combination therapy
- climate change
- cell free